GENEDX HOLDINGS CORP (WGS)

GeneDx to Participate in Upcoming Investor Conference

GeneDx Fuels Rare Disease Drug Discovery with Launch of GeneDx Discover

GeneDx Announces Heidi Chen as Chief Legal Officer and Corporate Secretary

Meet the Healthcare Stock That Produced Nvidia-Sized Gains in Less Than a Year

New GeneDx Study Reveals Racial Disparities in Genetic Diagnosis Due to Systemic Barriers, Not Diagnostic Yields

GeneDx to Highlight Key Research Findings at American Society of Human Genetics (ASHG) Annual Meeting

Notable Tuesday Option Activity: CALX, DKS, WGS

Tuesday Sector Leaders: Waste Management, Diagnostics

GeneDx Reports Third Quarter 2024 Financial Results and Business Highlights

Groundbreaking GUARDIAN Study Shows Benefits of Adding Genome Sequencing to Newborn Screening; Augments and Improves Standard Newborn Screening

Tuesday Sector Leaders: Diagnostics, Biotechnology Stocks

GeneDx to Showcase Data from Largest Genomic Newborn Screening Cohort of 14,000 Newborns

GeneDx to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024

GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GeneDx Stock Rocketed 1310% In Dramatic Turnaround Powered By DNA Analytics

The company provides sequencing tools to help diagnose children with rare diseases.

GeneDx to Participate in Fall Investor Conferences

Commit To Purchase GeneDx Holdings At $22.50, Earn 27.2% Annualized Using Options

GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WGS Stock Earnings: GeneDx Hldgs Beats EPS, Beats Revenue for Q2 2024

WGS stock results show that GeneDx Hldgs beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

WGS Stock Earnings: GeneDx Hldgs Beats EPS, Beats Revenue for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips GeneDx Hldgs (NASDAQ:WGS) just reported results for the second quarter of 2024....

GeneDx Reports Second Quarter 2024 Financial Results and Business Highlights

GeneDx Announces Whole Genome Sequencing (WGS) Product Enhancements to Accelerate Diagnoses for More Patients

GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing

GeneDx Holdings Corp. (NASDAQ: WGS) has soared 1,101% this year, attributed to its mix shift towards exome/genome testing and record high margins.

GeneDx to Report Second Quarter 2024 Financial Results on Tuesday, July 30, 2024

GeneDx to Report Second Quarter 2024 Financial Results on Tuesday, July 30, 2024

GeneDx (Nasdaq: WGS) today announced it will release financial results for the second quarter of 2024 after the market closes on Tuesday, July 30, 2024....

7 Small-Cap Stocks With Massive Potential Returns

Explore these small-cap stocks with high potential in health care, REITs, entertainment, hardware, finance, and distribution industries.

GeneDx Announces Collaboration with Epic Aura to Expand Access to Rapid Whole Genome Sequencing (rWGS) Services to Inform Diagnosis in Affected Pediatric and Neonatal Patients

GeneDx Announces Collaboration with Epic Aura to Expand Access to Rapid Whole Genome Sequencing (rWGS) Services to Inform Diagnosis in Affected Pediatric and Neonatal Patients

-- New integration to streamline access for health systems and improve provider and patient journeys using Epic for electronic connections -- -- Increases...